Three separate antitrust settlements covering some of the most commonly prescribed generic drugs in the country have reached final court approval, and the claims window is open for people who paid out of pocket for those medications over a decade-long stretch. The combined pool totals roughly $533 million, and the deadline to file a claim is the same across all three settlements.
The Antitrust Case Behind Three Settlements
The payouts stem from In re Generic Pharmaceuticals Pricing Antitrust Litigation, a sprawling federal case, No. 2:16-MD-2724, before Judge Cynthia M. Rufe in the U.S. District Court for the Eastern District of Pennsylvania. According to the settlement summary maintained by Open Class Actions, so-called end-payer plaintiffs — consumers and third-party payers such as insurers and employers with self-funded drug plans — allege that generic-drug manufacturers coordinated to fix, raise, and stabilize prices, rig bids, and allocate customers across roughly 200 commonly prescribed generic medications, including drugs such as levothyroxine, gabapentin, and pravastatin. The court has granted final approval to three of the resulting settlements, which are now paying claims together: $275 million from Sandoz Inc. and Fougera Pharmaceuticals Inc., $200 million from Sun Pharmaceutical Industries and Taro Pharmaceuticals U.S.A., and $58 million combined from Heritage Pharmaceuticals and Apotex Corp. The settling companies deny liability, and litigation continues against manufacturers that have not settled.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
Who Can File and Which Drugs Are Covered
Eligibility runs to people and entities in every state except Indiana and Ohio, plus the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, who indirectly purchased or reimbursed the cost of one or more of the named generic drugs — other than for resale — between May 1, 2009, and December 31, 2019. Consumers can file against the Sandoz and Sun/Taro settlements; third-party payers such as insurers and self-funded employer plans can file against all three, plus the Heritage and Apotex funds. The list of covered medications runs to roughly 200 generic drugs and includes widely prescribed names such as levothyroxine for thyroid conditions, pravastatin and propranolol for heart and blood-pressure treatment, gabapentin for nerve pain, glyburide for diabetes, and doxycycline, among many others; the full list with National Drug Code numbers is posted on the official settlement website.
Unlike some class-action settlements that pay automatically, this one requires documentation. Consumers must list each covered drug they bought and upload a receipt, invoice, pharmacy purchase record, or account statement showing at least one purchase during the class period, and the claim form is signed under penalty of perjury. Third-party payers must submit transaction-level data instead, including National Drug Code numbers, fill dates, amounts billed and paid net of co-pays, and covered-lives counts. Submitting a claim does not guarantee payment — the claims administrator can reject or reduce a claim for inadequate proof, though a dispute process described in the claim form is available if that happens. No claims-recovery firm or third-party service is required; filing directly on the official settlement site is free.
How the Payout Is Calculated
No fixed per-person figure exists. After court-approved attorneys’ fees, litigation expenses, service awards, and administrative costs are deducted from each of the three funds, what remains is distributed on a pro rata basis under a court-approved plan of allocation, in proportion to how much each claimant spent on the named drugs during the decade-long class period. Because the money is split only among people who actually file valid claims, a lower response rate can mean a larger share for the people who do. Any interest that accrues on the funds while they await distribution is included in the pro rata split.
The Nov. 9 Deadline and a Separate, Larger Program
Claim forms must be submitted online or postmarked by mail no later than November 9, 2026, and late submissions will not be paid. That single date applies to all three end-payer settlements described here, even though they involve different manufacturers and different fund sizes. Open Class Actions’ tracker also flags a related but legally distinct program: a separate $478.5 million agreement between Sandoz and a coalition of state attorneys general compensates consumers through a different process and is not part of the $533 million end-payer total covered by this claim form. The two programs share a defendant and a subject matter but are not the same fund, and the source cited above keeps them explicitly separate rather than merging the totals.
What the Settlements Do and Do Not Resolve
The settling manufacturers deny liability, and the notice is explicit that no trial has been held and no court has found that any law was broken; the settlements simply resolve the disputed claims. The underlying litigation continues against generic-drug makers that have not reached a settlement, which means additional funds could still be added to this litigation down the road, separate from the three programs paying out now. Because payment amounts depend on both a claimant’s own documented purchases and the total number of valid claims filed across the class, there is no way to estimate an individual payout in advance — the pro rata design only resolves once the claims window closes and the court authorizes a distribution date.
Inside the guide
A 5-tab Excel tracker pre-filled with all 51 state unclaimed-property offices, the source vault of 12 official places money sits, and a step-by-step filing walkthrough.
The Settlement & Refund Recovery System includes a 36-page guide, a 5-tab Excel tracker pre-filled with all 51 state unclaimed-property offices and the four-date rule for reading a settlement notice.
Open The Settlement & Refund Recovery System.
AI tools assisted in researching and drafting this article, which was reviewed prior to publication.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
